BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today reported financial results for the third quarter of fiscal 2012. Array reported revenue of $19.1 million for the third quarter of fiscal 2012, compared to revenue of $17.8 million for the same period in fiscal 2011. Array reported a net loss of $8.2 million, or ($0.11) per share, for the third quarter, compared to a net loss of $11.5 million, or ($0.20) per share, for the same period last year. The net loss improved due to increased revenue and reduced total spending in the current quarter. The Company spent $16.1 million on proprietary research and development for the quarter to advance its clinical development and discovery programs compared to $15.9 million during the same period last year. Array ended the third quarter of fiscal 2012 with $100 million in cash, cash equivalents and marketable securities.
